Physician profile
James A Morse
NPI 1942246988
$6,815.49
in general payments reported to CMS, 2019-2025
49 companies · $18.87 in 2025
The $18.87 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,119 · 2020: $448 · 2021: $1,133 · 2022: $1,396 · 2023: $1,324 · 2024: $1,377 · 2025: $18.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,720.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $828.03 | 2019-2024 | |
| Amgen INC. | $747.05 | 2019-2024 | Repatha, Otezla |
| Lilly USA, LLC | $680.94 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $642.86 | 2019-2024 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $552.69 | 2022-2024 | Freestyle Libre 3, Eterna |
| Pfizer INC. | $542.78 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $369.72 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $227.55 | 2019-2024 | Eliquis, Camzyos |
| Astellas Pharma US INC | $194.64 | 2019-2023 | Veozah |
| Astrazeneca Pharmaceuticals LP | $157.35 | 2019-2024 | Airsupra |
| Amarin Pharma, INC. | $156.57 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $141.68 | 2021-2024 | |
| Glaxosmithkline, LLC. | $129.35 | 2021-2024 | Arexvy, Shingrix |
| Daiichi Sankyo INC. | $126.54 | 2019-2024 | Injectafer |
| Janssen Pharmaceuticals, INC | $124.35 | 2019-2024 | Xarelto |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Morse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.